ArticleFrontiers in cellular and infection microbiology2025
Early diagnosis and prognostic prediction of secondary bloodstream infections caused by
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carbapenem-resistantFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Secondary bloodstream infections (sBSI) caused by Methods: The multicenter, retrospective study enrolled 4,267 ICU patients with Results: The AB-sBSI risk diagnosis model, constructed with 11 features, identified red cell distribution width as the most significant predictor. The AdaBoost model outperformed both comparative models (Linear Discriminant Analysis, Logistic Regression, LinearSVC) and the conventional biomarker C-reactive protein (AUC = 0.66), with AUCs of 0.937 in training and 0.786 in validation. For 30-day mortality prediction, another model based on 11 features selected lymphocyte count as the most influential variable. The AdaBoost model showed prominent efficacy, surpassing other model (Multilayer Perceptron, BernoulliNB, SGD) and achieving AUC values of 0.986 in training and 0.821 in validation. Conclusion: We developed two ML based models for predicting AB-sBSI risk and 30-day mortality. As a preliminary exploration, both models have been converted into accessible web tools. These tools are designed to assist clinicians in making informed decisions and promptly adjusting treatment strategies for critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.